339 related articles for article (PubMed ID: 36719370)
21. Genetic and immunologic evaluation of children with inborn errors of immunity and severe or critical COVID-19.
Abolhassani H; Delavari S; Landegren N; Shokri S; Bastard P; Du L; Zuo F; Hajebi R; Abolnezhadian F; Iranparast S; Modaresi M; Vosughimotlagh A; Salami F; Aranda-Guillén M; Cobat A; Marcotte H; Zhang SY; Zhang Q; Rezaei N; Casanova JL; Kämpe O; Hammarström L; Pan-Hammarström Q
J Allergy Clin Immunol; 2022 Nov; 150(5):1059-1073. PubMed ID: 36113674
[TBL] [Abstract][Full Text] [Related]
22. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
23. No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients.
Philippot Q; Bastard P; Puel A; Casanova JL; Cobat A; Laouénan C; Tardivon C; Crestani B; Borie R
Respir Res; 2023 Mar; 24(1):87. PubMed ID: 36941652
[TBL] [Abstract][Full Text] [Related]
24. Inherited and acquired errors of type I interferon immunity govern susceptibility to COVID-19 and multisystem inflammatory syndrome in children.
Bucciol G; ; Meyts I
J Allergy Clin Immunol; 2023 Apr; 151(4):832-840. PubMed ID: 36841740
[TBL] [Abstract][Full Text] [Related]
25. Human genetic and immunological determinants of critical COVID-19 pneumonia.
Zhang Q; Bastard P; ; Cobat A; Casanova JL
Nature; 2022 Mar; 603(7902):587-598. PubMed ID: 35090163
[TBL] [Abstract][Full Text] [Related]
26. The role of interferon in the thymus.
Martinez RJ; Hogquist KA
Curr Opin Immunol; 2023 Oct; 84():102389. PubMed ID: 37738858
[TBL] [Abstract][Full Text] [Related]
27. Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona.
Solanich X; Rigo-Bonnin R; Gumucio VD; Bastard P; Rosain J; Philippot Q; Perez-Fernandez XL; Fuset-Cabanes MP; Gordillo-Benitez MÁ; Suarez-Cuartin G; Boza-Hernandez E; Riera-Mestre A; Parra-Martínez A; Colobran R; Antolí A; Navarro S; Rocamora-Blanch G; Framil M; Calatayud L; Corbella X; Casanova JL; Morandeira F; Sabater-Riera J
J Clin Immunol; 2021 Nov; 41(8):1733-1744. PubMed ID: 34570326
[TBL] [Abstract][Full Text] [Related]
28. Management and outcome of COVID-19 in CTLA-4 insufficiency.
Ochoa S; Abers MS; Rosen LB; Rump A; Howe K; Lieberman JA; Wright BL; Suez D; Krausz M; Grimbacher B; Lionakis MS; Uzel G
Blood Adv; 2023 Oct; 7(19):5743-5751. PubMed ID: 37406177
[TBL] [Abstract][Full Text] [Related]
29. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.
Manry J; Bastard P; Gervais A; Le Voyer T; Rosain J; Philippot Q; Michailidis E; Hoffmann HH; Eto S; Garcia-Prat M; Bizien L; Parra-Martínez A; Yang R; Haljasmägi L; Migaud M; Särekannu K; Maslovskaja J; de Prost N; Tandjaoui-Lambiotte Y; Luyt CE; Amador-Borrero B; Gaudet A; Poissy J; Morel P; Richard P; Cognasse F; Troya J; Trouillet-Assant S; Belot A; Saker K; Garçon P; Rivière JG; Lagier JC; Gentile S; Rosen LB; Shaw E; Morio T; Tanaka J; Dalmau D; Tharaux PL; Sene D; Stepanian A; Mégarbane B; Triantafyllia V; Fekkar A; Heath JR; Franco JL; Anaya JM; Solé-Violán J; Imberti L; Biondi A; Bonfanti P; Castagnoli R; Delmonte OM; Zhang Y; Snow AL; Holland SM; Biggs CM; Moncada-Vélez M; Arias AA; Lorenzo L; Boucherit S; Anglicheau D; Planas AM; Haerynck F; Duvlis S; Ozcelik T; Keles S; Bousfiha AA; El Bakkouri J; Ramirez-Santana C; Paul S; Pan-Hammarström Q; Hammarström L; Dupont A; Kurolap A; Metz CN; Aiuti A; Casari G; Lampasona V; Ciceri F; Barreiros LA; Dominguez-Garrido E; Vidigal M; Zatz M; van de Beek D; Sahanic S; Tancevski I; Stepanovskyy Y; Boyarchuk O; Nukui Y; Tsumura M; Vidaur L; Tangye SG; Burrel S; Duffy D; Quintana-Murci L; Klocperk A; Kann NY; Shcherbina A; Lau YL; Leung D; Coulongeat M; Marlet J; Koning R; Reyes LF; Chauvineau-Grenier A; Venet F; Monneret G; Nussenzweig MC; Arrestier R; Boudhabhay I; Baris-Feldman H; Hagin D; Wauters J; Meyts I; Dyer AH; Kennelly SP; Bourke NM; Halwani R; Sharif-Askari FS; Dorgham K; Sallette J; Sedkaoui SM; AlKhater S; Rigo-Bonnin R; Morandeira F; Roussel L; Vinh DC; Erikstrup C; Condino-Neto A; Prando C; Bondarenko A; Spaan AN; Gilardin L; Fellay J; Lyonnet S; Bilguvar K; Lifton RP; Mane S; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Anderson MS; Boisson B; Béziat V; Zhang SY; Andreakos E; Hermine O; Pujol A; Peterson P; Mogensen TH; Rowen L; Mond J; Debette S; de Lamballerie X; Burdet C; Bouadma L; Zins M; Soler-Palacin P; Colobran R; Gorochov G; Solanich X; Susen S; Martinez-Picado J; Raoult D; Vasse M; Gregersen PK; Piemonti L; Rodríguez-Gallego C; Notarangelo LD; Su HC; Kisand K; Okada S; Puel A; Jouanguy E; Rice CM; Tiberghien P; Zhang Q; Casanova JL; Abel L; Cobat A
Proc Natl Acad Sci U S A; 2022 May; 119(21):e2200413119. PubMed ID: 35576468
[TBL] [Abstract][Full Text] [Related]
30. Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital.
Chauvineau-Grenier A; Bastard P; Servajean A; Gervais A; Rosain J; Jouanguy E; Cobat A; Casanova JL; Rossi B
J Clin Immunol; 2022 Apr; 42(3):459-470. PubMed ID: 35083626
[TBL] [Abstract][Full Text] [Related]
31. Type I and type III interferons: From basic biology and genetics to clinical development for COVID-19 and beyond.
Andreakos E;
Semin Immunol; 2024 Mar; 72():101863. PubMed ID: 38271892
[TBL] [Abstract][Full Text] [Related]
32. Human IRF1 governs macrophagic IFN-γ immunity to mycobacteria.
Rosain J; Neehus AL; Manry J; Yang R; Le Pen J; Daher W; Liu Z; Chan YH; Tahuil N; Türel Ö; Bourgey M; Ogishi M; Doisne JM; Izquierdo HM; Shirasaki T; Le Voyer T; Guérin A; Bastard P; Moncada-Vélez M; Han JE; Khan T; Rapaport F; Hong SH; Cheung A; Haake K; Mindt BC; Pérez L; Philippot Q; Lee D; Zhang P; Rinchai D; Al Ali F; Ahmad Ata MM; Rahman M; Peel JN; Heissel S; Molina H; Kendir-Demirkol Y; Bailey R; Zhao S; Bohlen J; Mancini M; Seeleuthner Y; Roelens M; Lorenzo L; Soudée C; Paz MEJ; González ML; Jeljeli M; Soulier J; Romana S; L'Honneur AS; Materna M; Martínez-Barricarte R; Pochon M; Oleaga-Quintas C; Michev A; Migaud M; Lévy R; Alyanakian MA; Rozenberg F; Croft CA; Vogt G; Emile JF; Kremer L; Ma CS; Fritz JH; Lemon SM; Spaan AN; Manel N; Abel L; MacDonald MR; Boisson-Dupuis S; Marr N; Tangye SG; Di Santo JP; Zhang Q; Zhang SY; Rice CM; Béziat V; Lachmann N; Langlais D; Casanova JL; Gros P; Bustamante J
Cell; 2023 Feb; 186(3):621-645.e33. PubMed ID: 36736301
[TBL] [Abstract][Full Text] [Related]
33. Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19.
Eto S; Nukui Y; Tsumura M; Nakagama Y; Kashimada K; Mizoguchi Y; Utsumi T; Taniguchi M; Sakura F; Noma K; Yoshida Y; Ohshimo S; Nagashima S; Okamoto K; Endo A; Imai K; Kanegane H; Ohnishi H; Hirata S; Sugiyama E; Shime N; Ito M; Ohge H; Kido Y; Bastard P; Casanova JL; Ohara O; Tanaka J; Morio T; Okada S
J Clin Immunol; 2022 Oct; 42(7):1360-1370. PubMed ID: 35764767
[TBL] [Abstract][Full Text] [Related]
34. Differential interferon-α subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection.
Schuhenn J; Meister TL; Todt D; Bracht T; Schork K; Billaud JN; Elsner C; Heinen N; Karakoese Z; Haid S; Kumar S; Brunotte L; Eisenacher M; Di Y; Lew J; Falzarano D; Chen J; Yuan Z; Pietschmann T; Wiegmann B; Uebner H; Taube C; Le-Trilling VTK; Trilling M; Krawczyk A; Ludwig S; Sitek B; Steinmann E; Dittmer U; Lavender KJ; Sutter K; Pfaender S
Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35131898
[TBL] [Abstract][Full Text] [Related]
35. Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients with Severe Coronavirus Disease 2019 Pneumonia.
Vanker M; Särekannu K; Fekkar A; Jørgensen SE; Haljasmägi L; Kallaste A; Kisand K; Lember M; Peterson P; Menon M; Hussell T; Knight S; Moore-Stanley J; Bastard P; Zhang SY; Mogensen TH; Philippot Q; Zhang Q; Puel A; Casanova JL; Kisand K
J Interferon Cytokine Res; 2023 Sep; 43(9):379-393. PubMed ID: 37253131
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.
Steiner S; Schwarz T; Corman VM; Gebert L; Kleinschmidt MC; Wald A; Gläser S; Kruse JM; Zickler D; Peric A; Meisel C; Meyer T; Staudacher OL; Wittke K; Kedor C; Bauer S; Besher NA; Kalus U; Pruß A; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
Front Immunol; 2022; 13():840126. PubMed ID: 35359967
[TBL] [Abstract][Full Text] [Related]
37. Autoantibodies targeting type I interferons: Prevalence, mechanisms of induction, and association with viral disease susceptibility.
Hale BG
Eur J Immunol; 2023 Jun; 53(6):e2250164. PubMed ID: 37027328
[TBL] [Abstract][Full Text] [Related]
38. Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease.
Busnadiego I; Abela IA; Frey PM; Hofmaenner DA; Scheier TC; Schuepbach RA; Buehler PK; Brugger SD; Hale BG
PLoS Biol; 2022 Jul; 20(7):e3001709. PubMed ID: 35788562
[TBL] [Abstract][Full Text] [Related]
39. Dysregulated early transcriptional signatures linked to mast cell and interferon responses are implicated in COVID-19 severity.
MacCann R; Leon AAG; Gonzalez G; Carr MJ; Feeney ER; Yousif O; Cotter AG; de Barra E; Sadlier C; Doran P; Mallon PW
Front Immunol; 2023; 14():1166574. PubMed ID: 37261339
[TBL] [Abstract][Full Text] [Related]
40. Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors.
Quarleri J; Delpino MV
Cytokine Growth Factor Rev; 2021 Apr; 58():55-65. PubMed ID: 33608189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
